Q-omics provides the consensus-scored RPL39P16 profile across patient tissues and cancer cell-line models. RPL39P16 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL39P16 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RPL39P16 RNA expression shows 18,723 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where RPL39P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL39P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL39P16 survival associations across molecular data types. RPL39P16 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL39P16 RNA expression–survival associations across cancer types. High RPL39P16 expression shows unfavorable associations in LIHC, MESO and LGG, but favorable associations in KIRC, READ and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL39P16 RNA expression.
This table summarizes RPL39P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL39P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL39P16 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, CHOL, STAD and LUSC. The HNSC box plot shows higher RPL39P16 RNA expression in tumor versus normal tissue (log2 FC = +0.631, t-test p < 0.001).
This table shows molecular features associated with RPL39P16 in patient tissues and cancer cell lines. In patient samples, RPL39P16 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
